NasdaqCM - Delayed Quote USD

Leap Therapeutics, Inc. (LPTX)

3.2500 +0.0800 (+2.52%)
At close: April 26 at 4:00 PM EDT
3.2000 -0.05 (-1.54%)
After hours: April 26 at 6:55 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Douglas E. Onsi J.D. CFO, General Counsel, Treasurer & Secretary, President, CEO & Director 1.04M -- 1969
Mr. Augustine J. Lawlor Chief Operating Officer 713.57k -- 1957
Dr. Cynthia A. Sirard Chief Medical Officer 708.64k -- 1970
Dr. Jason S. Baum Ph.D. Chief Scientific Officer -- -- 1979
Mr. Mark O'Mahony Chief Manufacturing Officer -- -- 1971
Ms. Christine M. Granfield VP and Head of Regulatory Affairs & Quality -- -- 1968

Leap Therapeutics, Inc.

47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
United States
617 714 0360 https://www.leaptx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
54

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Corporate Governance

Leap Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Leap Therapeutics, Inc. Earnings Call

Related Tickers

PDSB PDS Biotechnology Corporation
3.2700
+0.31%
 
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
 
CRVS Corvus Pharmaceuticals, Inc.
1.4500
-2.03%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
MREO Mereo BioPharma Group plc
2.7400
-2.49%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
 
OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%
 
XFOR X4 Pharmaceuticals, Inc.
1.1650
+3.10%
 
ELEV Elevation Oncology, Inc.
3.6200
-0.69%